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Background. The aim of this study is to investigate the ocular thermographic profiles in age-related macular degeneration (AMD)
eyes and age-matched controls to detect possible hemodynamic abnormalities, which could be involved in the pathogenesis of
the disease. Methods. 32 eyes with early AMD, 37 eyes with atrophic AMD, 30 eyes affected by untreated neovascular AMD, and
43 eyes with fibrotic AMD were included. The control group consisted of 44 healthy eyes. Exclusion criteria were represented by
any other ocular diseases other than AMD, tear film abnormalities, systemic cardiovascular abnormalities, diabetes mellitus, and a
body temperature higher than 37.5∘C. A total of 186 eyes without pupil dilation were investigated by infrared thermography (FLIR
A320).The ocular surface temperature (OST) of three ocular points was calculated bymeans of an image processing technique from
the infrared images. Two-sample 𝑡-test and one-way analysis of variance (ANOVA) test were used for statistical analyses. Results.
ANOVA analyses showed no significant differences among AMD groups (P value> 0.272). OST in AMD patients was significantly
lower than in controls (P > 0.05). Conclusions. Considering the possible relationship between ocular blood flow and OST, these
findings might support the central role of ischemia in the pathogenesis of AMD.
1. Introduction
Age-related macular degeneration (AMD) represents the
primary cause of visual deterioration and legal blindness in
patients over 60 years old [1] and the third leading cause
worldwide [2]. It is a complex and multifactorial disease due
to degenerative changes of the choroid and choriocapillaris,
the retinal pigmented epithelium (RPE), Bruch’s membrane,
and photoreceptors [3–5] but the histopathological mecha-
nisms are not completely clarified.
The International Classification and Grading System for
age-related maculopathy and age-related macular degener-
ation recognizes an early stage of the disease (age-related
maculopathy or ARM) and a late stage (AMD) divided in dry
AMD (or geographic atrophy) and wet AMD (or neovascular
AMD) [6].
Despite intensive research, the pathogenicmechanisms of
AMD are poorly understood. The role of genetics has been
widely confirmed [7–11] as suggested by the recurrence of the
disease in some families [12] and the identification of several
loci associated with a higher risk of AMD [13–19]. Oxidative
damage [20] and an abnormal inflammatory response [7, 8,
21–29] have been also implicated in AMD development.
Furthermore, some authors strongly support the hypoth-
esis of an ischemic etiology of the disease [30–34] related to
choroidal and retinal blood flow abnormalities [31–40].
Fluorescein angiography and indocyanine green angiog-
raphy [39, 40], laser Doppler flowmeter [31–33, 39, 41],
ocular blood flow tonometry [42], and digitised ultrasound
[43] have allowed evaluating ocular blood flow alterations
in patients with AMD, sustaining the idea that a vascular
ischemic mechanism plays a central role in the pathogenesis
of the disease.
In the present study polypoidal choroidal vasculopathy
(PCV) was excluded as high flow values in this relatively
rare subtype of macular degeneration might have biased our
estimates of choroidal blood flow in AMD [44–46].
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Infrared thermography has been used to measure ocular
surface temperature (OST) which is believed to represent
an indirect marker of ocular hemodynamics: a possible
correlation between OST and ocular blood flow has been
suggested by several previous studies [47–55].
At present no information about OST in AMD is avail-
able.
The aim of this study is to investigate the ocular ther-
mographic profiles in AMD eyes to detect possible hemo-
dynamic abnormalities, which could be involved in the
pathogenesis of the disease.
2. Materials and Methods
One hundred and eighteen patients (34M/84 F, 79 ± 2 years)
affected by AMD and 44 healthy subjects (21 F/23M, 72 ± 7
years) were enrolled and recruited at the Eye Clinic, Depart-
ment of Surgery and Translational Medicine, University of
Florence, Italy. The study followed the tenets of the Declara-
tion ofHelsinki andwas approved by the Institutional Review
Board at the University of Florence. Informed consent was
obtained from each patient after explanation of the purpose
and description of the procedures of the study. The presence
of other ocular or systemic pathologies was carefully investi-
gated. Specifically, exclusion criteria were glaucomatous optic
neuropathy, high myopia, retinal angiomatous proliferation
(RAP), polypoidal choroidal vasculopathy (PCV), and other
retinal and choroidal diseases except for typical AMD,
corneal or tear film abnormalities, and diabetes mellitus and
a body temperature higher than 37.5∘C.
All the subjects included in the study underwent a
comprehensive clinical evaluation including best corrected
visual acuity measurement, anterior segment evaluation,
tonometry, and biomicroscopy of the posterior pole.
Optical coherence tomography (OCT) scan (Topcon 3D
OCT-1000, Topcon Medical Systems Inc, Oakland, NJ, USA)
and/or fluorescein angiography (FA) was performed when
active choroidal neovascularization (CNV) was diagnosed or
suspected.
Three observers (AS, GG, and LF) evaluated indepen-
dently all eyes. The same observers classified the 142 selected
AMD eyes into four subsets depending on the form of AMD
diagnosed at the time of the thermographic acquisition.
Specifically, we divided the AMD eyes into the following
groups: twenty-nine patients (32 eyes) with ARM (20 F/9M,
77 ± 7 years), 27 patients (37 eyes) with atrophic AMD
(19 F/7M, 82 ± 6 years), 29 patients (30 eyes) affected by
neovascular AMD (18 F/11M, 77 ± 7 years), and 33 patients
(43 eyes) with fibrotic AMD (27 F/6M, 79 ± 7 years) were
included in the study.
None of the neovascular AMD patients had ever been
treated with photodynamic therapy or intravitreal antiangio-
genic drugs prior to thermographic examination. Specifically,
these patients underwent infrared thermography before the
first planned intravitreal injection on the same day.
Fibrotic AMD group consisted of eyes with previous
wet AMD which evolved to a fibrous macular scar with or
without treatment that did not present any sign of vascular
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Figure 1: Infrared image of an eye. 1 is nasal cantus, 2 is corneal
centre, and 3 is temporal cantus.
activity (angiographic leakage or OCT fluid) at the time of
the thermographic measurement.
The control group consisted of 44 age-matched subjects
with healthy eyes who underwent routine clinical exami-
nation. One eye was randomly chosen for thermographic
evaluation.
A total of 186 eyes (142 AMD and 44 controls) were
investigated by infrared thermography.
The pupils were not dilated in order to avoid possible
influence of pupil diameter on the thermographic profile.
The thermocamera used was the FLIR A320 (FLIR Sys-
tem, USA) with an image resolution of 320 × 240 pixels
and image frequency of 30Hz. The detectors time constant
was 12ms with accuracy ±2∘C/±2% and sensibility of 0.05∘C
at +30∘C. OST measurements were carried out by only one
examiner in order to avoid interexaminer variation, in a
room without windows, illuminated with neon lights. Both
temperature and humidity were constantly monitored and
maintained to an average of 20.8±2.7∘C and 42±9%by using
an air conditioning system.
The same procedure was applied for each thermographic
acquisition. Subjects remained in the test-room for 20 min-
utes, so that their own body temperature could adapt to
the climatic condition of test-room. Then, subject’s chin
was positioned on an ophthalmic chinrest in front of the
thermocamera, whose lens was positioned at 300mm. The
subject was asked to keep both eyes closed for 10 s before
starting the measurement and to keep both eyes widely open
during the thermographic acquisition (7 s at 30Hz), so that
just one recording was sufficient for evaluating both eyes.
Three recordings were taken for each subject.
For each thermographic acquisition only the first frame
corresponding to the eye opening was selected for further
analysis, in order to avoid the influence of the tear-film
evaporation. A Matlab code (R2009b, Mathworks, USA) was
used to calculate, from the selected frames, the temperatures
of three anatomical points corresponding to the principal
anatomical areas of the anterior eye: corneal centre (P
2
) and
temporal and nasal canti (P
3
and P
1
), as shown in Figure 1.
Analysis of variance (one-way ANOVA, Stata 12.1 soft-
ware, StataCorp, USA) was applied in order to assess the
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Table 1: Ocular surface temperature of all three points expressed as
means ± one standard deviation for AMD groups and controls.
Groups 𝑇1 [∘C] 𝑇2 [∘C] 𝑇3 [∘C]
ARM 35.68 ± 0.42 34.21 ± 0.53 34.91 ± 0.47
Atrophic AMD 35.59 ± 0.44 34.08 ± 0.47 34.83 ± 0.54
Neovascular AMD 35.60 ± 0.61 34.14 ± 0.75 34.79 ± 0.69
Fibrotic AMD 35.58 ± 0.31 34.03 ± 0.42 34.85 ± 0.42
Controls 35.89 ± 0.52 34.64 ± 0.84 35.23 ± 0.60
measurements repeatability as well as the difference among
the temperatures of the three points selected for all groups
investigated. The same statistical analysis was also used to
assess whether there was a statistically significant difference
in the OST among AMD groups. Furthermore, unpaired t-
test (Stata 12.1 software, StataCorp, USA) was carried out
in order to compare the entire AMD population as well
as each AMD subgroup with controls. The differences were
considered statistically significant when 𝑃 value was less or
equal to 0.05.
3. Results
For each eye the average temperature of the three recordings
was considered, as ANOVA analyses showed no significant
differences among the three recordings.
A characteristic thermographic profile characterized by
higher temperatures at the extremities (P
1
and P
3
) and a
lower temperature in the corneal centre (P
2
) was found in all
subjects.
ANOVA tests showed that there was a statistically signifi-
cant difference among the temperatures of the three points for
both AMD groups (𝑃 value < 0.0001) and healthy controls (𝑃
value < 0.0001).
The average results for the four AMD subsets of patients
are summarized in Table 1. ANOVA tests showed no signif-
icant difference among AMD groups (𝑃 value > 0.272), as
shown in Figure 2.
Unpaired t-test showed a significant difference between
the totalAMDpopulation and controls in all points (𝑃 value<
0.009), as shown in Table 2 and Figure 3.
When statistically comparing each AMD group with
controls, a significant difference was found in all points (𝑃
value < 0.05), as shown in Table 3.
4. Discussion
Infrared thermography allows ocular hemodynamics evalua-
tion bymeasuring the heat radiated from the eye surface. Pre-
vious studies showed OST abnormalities in retinal vascular
disorders, such as arterial occlusive disease [47], central vein
occlusion [52], diabetic retinopathy [53], glaucoma [54, 55],
bacterial corneal ulcers [56], and dry eye syndrome [57]. In
the present study we evaluated OST in patients affected by
different forms of AMD.
Both AMD patients and healthy controls included in this
study showed a common thermography profile with a lower
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Figure 2: Average OST profiles of AMD patients and controls.
Table 2: Ocular surface temperature of all three points expressed as
means ± one standard deviation for all AMD patients and controls.
𝑇1 [∘C] 𝑇2 [∘C] 𝑇3 [∘C]
AMD 35.61 ± 0.44 34.11 ± 0.54 34.85 ± 0.52
Controls 35.89 ± 0.52 34.64 ± 0.84 35.23 ± 0.60
𝑃 value 0.009 0.001 0.001
temperature in the central cornea (point P
2
) and a higher
temperature at the extremities of the profile, in the nasal and
temporal scleroconjunctival areas (P
1
and P
3
).This result can
be explained by considering that the center of the cornea is
nonvascularised and more prone to tear evaporation, while
the extremities are located in areas with a relevant blood
supply and less influenced by the tear evaporation.
In our study the OST of AMD patients is significantly
lower than that of healthy subjects in the three chosen ocular
points. As OST is indirectly associated with blood perfusion,
its reduction may suggest a decrease in ocular blood flow.
This result strengthens the central role of ischemia in the
pathogenesis of AMD, in agreement with the hypothesis
that impairment in choroidal circulation may represent a
primary pathogenic mechanism leading to RPE senescence
and AMD [58, 59]. However, an OST reduction, indirectly
suggesting a blood flow decrease, does not support the role
of inflammation in the pathogenesis of the disease. In fact,
inflammation is usually associated with an increase in blood
perfusion that should lead to OST increase. Of course our
data does not exclude a role of inflammation in AMD onset
and progression because very limited inflammatory processes
may determine a relevant functional impact, in spite of the
poor influence on ocular hemodynamics and OST.
In the present study early or advanced and atrophic
or neovascular AMD do not show significant differences
in the OST. All AMD subgroups show a reduced surface
temperature value suggesting that hemodynamic abnormal-
ities may represent a common pathogenic pathway for the
different forms and stages of the disease. The physiopatho-
logical affinity between atrophic and neovascular AMD is in
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Figure 3: Comparison among the average OST profiles of all AMD
groups.
Table 3: 𝑃 values calculated from unpaired t-test carried out
between controls and each AMD subgroup.
Controls
𝑇1 [∘C] 𝑇2 [∘C] 𝑇3 [∘C]
ARM 0.052 0.008 0.011
Atrophic AMD 0.006 <0.0001 0.003
Neovascular AMD 0.036 0.009 0.006
Fibrotic AMD 0.001 <0.0001 0.001
agreement with that encountered in clinical practice where
some patients may show a dry AMD in one eye and an
exudative AMD in the other. Similarly, some patients may
start with an atrophic AMD later complicated by a CNV.
The lack of significant OST differences among the four
AMD subgroups and particularly between ARM and the
more advanced stages of the disease suggests that OST mea-
surements cannot be used for an early diagnosis ofCNVor for
monitoring the disease progression. Probably the evaluation
of the thermographic profile may be a reliable tool to appre-
ciate large vascular changes (like the ischemic alterations
involving thewhole choroid), butOSTmeasurement does not
have enough sensitivity to detect very small (even if clinically
very relevant) vascular abnormalities. We can speculate that
thermography could be used to detect possible choroidal
atrophic changes consequent to photodynamic therapy or to
repeated antivascular endothelial growth factor (anti-VEGF)
intravitreal injection.
Our study shows some limitations. OST evaluation is
only an indirect method for ocular blood supply assessment
and can be influenced by many factors (drugs assumption,
vascular diseases other than diabetes, smoking history, and
lifestyles). Moreover, the evaluation of OST distribution in
the cornea and in the contiguous scleroconjunctival areas
with our present technology provides very poor topographic
information about the location of possible intraocular vascu-
lar abnormalities. These limitations are innate in the present
procedure of OST evaluation and could be possibly overcome
by means of technological refinements.
It would be interesting to evaluate the influence of lesion
size and level of activity, as well as CNV subtypes (classic,
occult, and mixed) on the OST in further investigations.
5. Conclusions
Infrared thermography may be a helpful, noninvasive, and
not time-consuming method to be used in the evaluation of
patients with AMD. It could provide interesting information
about the physiopathology of the disease although at present
it does not seem suitable for the management of AMD
patients in a clinical setting.
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